AtriCure, Inc. (ATRC) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Atricure, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.057 2025 earnings conference call. This call is being recorded for replay 00:00:05.057 -- 00:00:10.223 purposes, and at this time, all participants are in listen-only mode. 00:00:10.223 -- 00:00:14.848 We will be facilitating a question and answer session following prepared remarks from 00:00:14.848 -- 00:00:19.954 HECURES management. I would now like to turn the call over to Marisa Beisch 00:00:19.954 -- 00:00:24.518 from the Gilmartin Group for a few introductory comments. 00:00:25.902 -- 00:00:31.079 Thank you. By now, you should have received a copy of the earnings press release. 00:00:31.079 -- 00:00:34.682 If you have not received a copy, please call 513-644-4484 00:00:34.682 -- 00:00:36.682 to 00:00:36.744 -- 00:00:39.347 have one emailed to you. 00:00:39.347 -- 00:00:43.651 Before we begin today, let me remind you that the company's remarks include forward-looking 00:00:43.651 -- 00:00:45.313 statements. 00:00:45.313 -- 00:00:49.557 Forward-looking statements are subject to numerous risks and uncertainties, 00:00:49.557 -- 00:00:54.262 many of which are beyond HRCUR's control, including risks and uncertainties described 00:00:54.262 -- 00:00:58.385 from time to time in HRCUR's SEC filings. 00:00:58.385 -- 00:01:04.192 These statements include, but are not limited to, financial expectations and guidance, 00:01:04.192 -- 00:01:08.758 expectations regarding the potential market opportunity for Atricure's franchises and 00:01:08.758 -- 00:01:10.480 growth initiatives, 00:01:10.480 -- 00:01:13.144 future product approvals and clearances, 00:01:13.144 -- 00:01:15.447 competition, reimbursement, 00:01:15.447 -- 00:01:17.890 and clinical trial outcomes. 00:01:17.890 -- 00:01:21.114 Atricure's results may differ materially from those pr...